Yes the article is missing a lot of things - it's pretty lazy. I am glad they included this snippet from Mel.
"Melinda Lancaster, whose daughter Katelin has Rett syndrome and was in the first clinical trial of Daybue, says her family’s life has been transformed since the treatment was approved in the US.“Her gross motor skills continue to improve. It kinda snuck up on me, but she’s eaten her whole breakfast by herself for the last two weeks using utensils. Incredible! Her balance just blows my mind, and she’s taken to walking more, especially over the last couple of weeks,” Lancester wrote on her blog last month."
NEU Price at posting:
$11.01 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)